Background and purpose: Histone deacetylases (HDACs) silence genes by deacetylating lysine residues in histones and other proteins. HDAC inhibitors (HDACi) represent a new class of compounds with anti-inflammatory activity. This study investigated whether treatment with a broad spectrum HDACi, suberoylanilide hydroxamic acid (SAHA), prevents the cardiac fibrosis as part of the cardiovascular remodelling in deoxycorticosterone acetate (DOCA)-salt rats. Experimental approach: Control and DOCA-salt rats were treated with SAHA (25 mg kg -1 day -1 s.c.) for 32 days; changes in cardiovascular structure and function were
INTRODUCTION
Chronic pathophysiological stress often leads to excessive collagen deposition (fibrosis) in the left ventricle of the heart, as part of the process of cardiovascular remodelling. Cardiac fibrosis is thought to be initiated by the actions of proinflammatory cytokines leading to fibroblast activation and infiltrating inflammatory cells (Brown et al, 2005a; Hinglais et al, 1994; Kanzaki et al, 2001; Ratcliffe et al, 2000) . The common sequence of events that occurs in response to an inflammatory insult can be summarized as haemostasis; recruitment of circulating immuneinflammatory cells; macrophage activation; activation of fibroblasts and formation of a provisional matrix; and remodelling of the granulomatous scar (Brown et al, 2005b) . This remodelling of the heart and blood vessels ultimately leads to a decrease in ventricular compliance together with ventricular hypertrophy, conduction abnormalities, increased blood pressure and endothelial dysfunction (Weber, 1996; Weber et al, 1993) .
Inflammatory gene expression, DNA repair and proliferation may be controlled by the degree of acetylation of histone and non-histone proteins produced by histone acetyltransferases (HATs) and histone deacetylases (HDACs) (Adcock, 2007; Halili et al, 2009) . HDAC inhibitors (HDACi) represent a new class of anti-cancer drugs with pleiotropic anti-inflammatory responses. HDACi prevent pro-inflammatory cytokine production with therapeutic effects reported in animal models of inflammatory diseases (Adcock, 2007; Blanchard & Chipoy, 2005; Lin et al, 2007; Halili et al, 2009; Tong et al, 2004) . Pro-inflammatory cytokines assist in the infiltration of inflammatory cells into the myocardium (Nicoletti & Michel, 1999; Rutschow et al, 2006; Westermann et al, 2006) . This initiates an inflammatory cascade liberating arachidonic acid and metabolites such as 12-lipoxygenase and 5-lipoxygenase derivatives, cysteinyl leukotrienes and thromboxanes with well-defined profibrotic properties (Cruz-Gervis et al, 2002; Levick et al, 2006; Wen et al, 2003) . The precise HDAC isoforms responsible for cardiovascular remodelling in vivo are not known, with evidence that class I (HDACs 1, 2, 3, 8 and 11), II (HDACs 4, 5, 6, 7, 9, 10) and III (sirtuins) generally have pro-hypertrophic, anti-hypertrophic and antiapoptotic functions in cardiomyocytes, respectively (McKinsey & Kass, 2007; Verdin et al, 2003; Zhang et al, 2002) . Some HDACi have been shown to blunt cardiac hypertrophy (Antos et al, 2003; Gallo et al, 2008; Kee et al, 2006; Kong et al, 2006) , but those studies did not consider the possibility that the anti-inflammatory effects of HDACi could control fibrosis and improve cardiac function. The development of HDACi with selectivity for individual isoforms is still in its infancy. It is also worth noting that there are relatively few truly HDAC-selective compounds and many of those that have been reported to show some selectivity in vitro against different HDAC enzymes have been found by us (Fairlie, Sweet et al; unpublished work) to be fairly toxic to normal human cells (cardiomyocytes, macrophages).
The present study has investigated whether the FDA-approved HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), prevents cardiovascular remodelling and improves cardiac function in DOCA-salt rats. SAHA is a broad-spectrum (class I and II) inhibitor of HDAC with moderate potency (IC 50 ~100 nM) that is being used to treat T-cell lymphoma (Richon, 2006) . Unlike most HDAC inhibitors, SAHA is also relatively non-toxic to normal cells and was therefore an appropriate choice for our in vivo study reported here. The present study establishes that SAHA decreases DOCAinduced cardiovascular remodelling in rats, as demonstrated by reductions in the increased systolic blood pressure, collagen deposition, cardiac stiffness, left ventricular hypertrophy, action potential duration and vascular dysfunction that are characteristic of the DOCA-salt rat as well as decreasing expression of inflammatory cytokines. These findings suggest that inhibition of class I and II HDACs may present a novel approach to preventing the development of these key indicators of cardiovascular remodelling.
MATERIALS AND METHODS

DOCA-salt hypertensive rats
Male Wistar rats (8-10 wk old) were obtained from the Central Animal Breeding House of The University of Queensland. All experimental protocols were approved by the Animal Experimentation Ethics Committee of The University of Queensland under the guidelines of the National Medical and Health Research Council, Australia. Rats were given ad libitum access to food and water and were housed in 12-h light/dark conditions. All treated rats were uninephrectomized. The rats were anesthetized with an intraperitoneal injection of Zoletil (tiletamine (25 mg kg -1 ) and zolazepam (25 mg kg -1 )) together with xylazine (10 mg kg -1 , Rompun); a lateral abdominal incision provided access to the kidney, and the left renal vessels and ureter were ligated. The left kidney was removed and weighed, and the incision site was sutured. Uninephrectomized rats were given no further treatment or were given 1% NaCl in the drinking water with subcutaneous injections of deoxycorticosterone acetate (DOCA) (25 mg in 0.4 ml of dimethylformamide every 4th day, DOCA-salt rats). SAHA (25 mg kg -1 dissolved in 80% dimethylformamide) was administered daily as a subcutaneous injection for 32 days, starting 4 days before surgery until experiments. Experiments were performed 28 days after surgery, as in previous studies (Chan et al, 2006; Fenning et al, 2005; Loch et al, 2007) .
Assessment of physiological parameters
Body weight, food and water intakes were measured daily. Systolic blood pressure was measured after 0, 2 and 4 weeks under light sedation with i.p. injection of Zoletil (tiletamine 15 mg kg -1 , zolazepam 15 mg kg -1 ), using an MLT1010 Piezo-Electric Pulse Transducer (ADInstruments) and inflatable tail-cuff connected to a MLT844 Physiological Pressure Transducer (ADInstruments) and PowerLab data acquisition unit (ADInstruments, Sydney, Australia). Rats were killed with an injection of pentobarbitone sodium (100 mg kg -1 ip). Blood was taken from the abdominal aorta and centrifuged, and the plasma was frozen. Plasma malondialdehyde concentrations were determined by HPLC (Sim et al, 2003) .
Isolated heart preparation
The left ventricular function of the rats in all treatment groups was assessed using the Langendorff heart preparation. Terminal anaesthesia was induced via i.p. injection of pentobarbitone sodium 100 mg kg -1 (Lethabarb ®). Once anaesthesia was achieved, heparin (1000 IU) was injected into the right femoral vein. Isovolumetric ventricular function was measured by inserting a latex balloon catheter into the left ventricle connected to a Capto SP844 MLT844 physiological pressure transducer and Chart software on a Maclab system. All left ventricular end-diastolic pressure values were measured by pacing the heart at 250 beats per minute using an electrical stimulator. End-diastolic pressures were obtained starting from 0mmHg up to 30mmHg. The right and left ventricles were separated and weighed. Diastolic stiffness constant (, dimensionless) was calculated as in previous studies (Chan et al, 2006; Fenning et al, 2005; Loch et al, 2007) .
Microelectrode studies on isolated left ventricular papillary muscles
Terminal anaesthesia was induced via i.p. injection of pentobarbitone sodium 100 mg kg -1 (Lethabarb®). The thorax was opened quickly, and the heart was removed. The left ventricular papillary muscles were quickly dissected in cold Tyrode physiological salt solution (in mM: 136.9 NaCl, 5.4 KCl, 1.0 MgCl 2 ·H 2 O, 0.4 NaH 2 PO 4 ·2H 2 O, 22.6 NaHCO 3 , 1.8 CaCl 2 ·2H 2 O, 5.5 glucose, 0.3 ascorbic acid, and 0.05 Na 2 EDTA) bubbled with 95% O 2 -5% CO 2 . Action potential duration (APD) at 20%, 50%, and 90% of repolarization, action potential amplitude, and action potential voltage over time (dV/dt max ) was calculated as in previous studies Woolf et al, 2006) . Contractile parameters measured were force of contraction and rate of change of force of contraction (dF/dt).
Organ bath studies
Thoracic aortic rings (4 mm in length) were suspended in an organ bath chamber with a resting tension of 10 mN. Cumulative concentration-response (contraction) curves were measured for noradrenaline; response (relaxation) curves were measured for acetylcholine and sodium nitroprusside in the presence of a submaximal (70%) contraction to noradrenaline (Allan et al, 2005; Chan et al, 2006) .
Organ weights
Following euthanasia, the heart, liver, kidneys and spleen were removed and blotted dry for weighing. Organ weights were normalized relative to the body weight at the time of their removal (in mg g -1 ).
Histology
Tissues were initially fixed for 3 days in Telly's fixative (100 ml of 70% ethanol, 5ml of glacial acetic acid and 10 ml of 40% formaldehyde) and then transferred into modified Bouin's fluid (85 ml of saturated picric acid, 5ml glacial acetic acid and 10 ml of 40% formaldehyde) for 2 days. The samples were then dehydrated and embedded in paraffin wax. Thin sections (10 m) of left ventricle were cut and stained with haematoxylin and eosin for determination of inflammatory cell infiltration. Monocytes and macrophages were identified by a trained observer under a high power (100X objective) microscope. Thick sections (15 m) were cut, stained with picrosirius red and image analysis under the laser scanning microscope was performed as previously described Loch et al, 2006) .
Cytokine analysis
Cytokines were detected in rat sera using Proteome Profiler Rat Cytokine Array Panel A (R&D Systems, MN, USA) according to manufacturer's instructions. Briefly, nitrocellulose membranes were incubated with 800 L of rat sera overnight at 4C with 15 L of detection antibody cocktail. After washing, streptavidin-HRP and chemiluminescent detection reagent were added sequentially. Multiple exposures to X-ray film were made for up to 30 min. Densitometric analysis of array images was performed using Java-based ImageJ version1.40g from NIH. The relative change in cytokine concentrations between sera from DOCA-salt rats ± SAHA treatment were measured and are presented as mean  SEM of three independent experiments (n = 3). The rat proteins that could be monitored by this kit were limited to 29 inflammatory markers: interleukins (1, 1, 1ra, 2, 3, 4, 6, 10, 13, 17) , TNF, IFN, GMCSF, RANTES, cytokine-induced neutrophil chemoattractants (CINC 1-3), interferoninducible protein (IP10), macrophage inflammatory proteins (MIP1, 3), tissue inhibitor of metalloproteinases (TIMP1), LPS-induced CXC chemokine (LIX), vascular endothelial growth factor (VEGF), monokine induced by IFN-gamma (MIG), soluble intercellular adhesion molecule (sICAM), L-selectin, CNTF, thymus chemokine and fractalkine. In further experiments, the RayBio Human Cytokine Antibody Array was used to detect whether treatment with SAHA at 5 or 50 M for 10h changed the expression of both pro-and active forms of human matrix metalloproteinases (MMP)-1, -2, -3, -8, -10 and -13 or tissue inhibitor of matrix metalloproteinases (TIMP)-1, -2 and -4 in culture medium of human monocytederived macrophages. In addition, gelatin zymography experiments were performed to assess the effect of SAHA at 5-500 M on purified active human recombinant MMP-2 and 9 activity.
Statistical analysis
All data sets were represented as mean ± standard error of mean (SEM). Comparisons of findings between groups were made via statistical analysis of data sets using oneway/two-way analysis of variance followed by the Duncan test to determine differences between treatment groups. A p-value of <0.05 was considered as statistically significant.
Drugs
Synthesis of SAHA
A mixture of aniline and suberic acid was melted at 190°C for 10 min and then, after cooling, the suberanilic acid was separated from suberic dianilide by extraction into aqueous KOH before acidification. The suberanilic acid was esterified (EtOH/H 2 SO 4 ) and subsequently treated with hydroxylamine to produce the hydroxamic acid (SAHA). The product showed no impurities either by reversed phase HPLC, NMR (1H, 13C) spectroscopy or mass spectrometry. Spectral data was in agreement with literature values (Stowell et al, 1995) .
DOCA, heparin, noradrenaline, acetylcholine and sodium nitroprusside were purchased from Sigma Chemical Company (St Louis, MO, U.S.A.). Noradrenaline, acetylcholine and sodium nitroprusside were dissolved in distilled water. DOCA was dissolved in dimethylformamide with mild heating.
RESULTS
Biometrics
DOCA-salt treated rats showed an increased water intake and failed to gain weight, as in previous studies (Table 1; Fenning et al., 2005; Mirkovic et al., 2002) . SAHA failed to alter body weight or water intake in the DOCA-salt rats; further, UNX rats treated with SAHA also failed to gain weight compared to vehicle-treated rats. There was no change in the food intake among the groups. Systolic blood pressure was increased in DOCA-salt rats when compared with UNX rats and this increase was attenuated by SAHA treatment (Table 1 ). The DOCA-salt rats showed left and right ventricular hypertrophy (increased LV+septum and RV wet weights) at 4 weeks, compared with UNX rats (Table 1 ) and this increase in organ weights of both ventricles was attenuated by SAHA treatment. DOCA-salt rats showed increased wet weights of liver, spleen and kidney that were unaltered by SAHA treatment (Table 1) . Plasma malondialdehyde concentrations, as a measure of oxidative stress, were increased in DOCA-salt rats; this increase was attenuated by SAHA treatment (Table  1) .
Rat chemokines and cytokines; matrix metalloproteinase activity
A chemokine/cytokine array kit was used to compare the effect of SAHA on plasma inflammatory mediators from DOCA-salt rats rather than ELISAs for individual cytokines since cytokines show marked redundancy. Visual inspection of Figure 1 reveals that SAHA suppressed the expression of all of these markers, except for CINC1 which was overexpressed, while it was difficult to deduce any change for RANTES, TIMP1 and LIX. Quantitative analysis by densitometry of the blots ( Figure  2 ) could only reliably place statistical significance on the more highly expressed proteins (IL1, IP10, IL1ra, GMCSF, IL10, fractalkine, VEGF, MIG). We conclude that SAHA has broad-spectrum anti-inflammatory activity in these DOCA-salt treated rats, clearly impacting the "cytokine storm" by reducing plasma concentrations of a diverse range of pro-inflammatory proteins.
Further, SAHA, a hydroxamate derivative and other hydroxamates (Leung et al, 2000; Halili et al, 2009 ) could possibly inhibit matrix metalloproteinase (MMP) expression or activity. To address this issue, we measured the expression of human MMPs and tissue inhibitors of matrix metalloproteinase (TIMPs) in culture medium of human monocyte-derived macrophages. Addition of SAHA (5 or 50 M) did not change MMP expression (data not shown). Further, using gelatin zymography, SAHA at 5 or 50 M showed no inhibition of MMP-2 and -9 activity whereas at 500 M, it showed a modest inhibition of MMP-2 activity (data not shown).
Left ventricular structure and function
Hearts from DOCA-salt rats showed increased diastolic stiffness that was attenuated by SAHA treatment (Table 1 ). The collagen content in the left ventricle of UNX rats (perivascular 20.03.6%, n=4, Figure 2 ; interstitial 1.10.1%, n=5; Figure 3 ) was increased in DOCA-salt rats (perivascular, 56.62.5%, n=4; interstitial 9.20.9%, n=5; Figure 3 ). These increases were attenuated by treatment with SAHA in the DOCA-salt rats (DOCA+SAHA: perivascular 381.2%, n=4; interstitial 4.60.5%, n=5). Collagen deposition was unaltered by SAHA treatment in the normotensive UNX rats (UNX+SAHA: perivascular 19.00.8%, n=4; interstitial 1.20.1%, n=5; Figure 3 ).
Spatial location of monocyte/macrophages (Figure 4) shows monocyte/macrophages in the left ventricle of UNX rats in very low numbers and always as single cells. The density of monocyte/macrophages found in the left ventricle of DOCA-salt rats was significantly greater than in UNX, and these cells were usually found in clusters of cells located at scar sites and throughout the interstitium and the areas of fibrosis. Very few infiltrating cells were found in scar tissue in DOCA-salt rats treated with SAHA, predominantly due to the decreased area of scar tissue within the left ventricle; few infiltrating cells were found in the perivascular areas (Figure 4) .
Microelectrode studies
Single cell microelectrode studies were performed on isolated left ventricular papillary muscles to quantify the changes in electrical conductance in the hypertrophied hearts. In hearts from the DOCA-salt rats, APD was markedly increased at 20%, 50% and 90% of repolarisation when compared with UNX hearts. Treatment with SAHA decreased the resting membrane potential and action potential amplitude in both treatment groups (Table 1 ). The increased action potential duration at 20% and 90% of repolarization in the DOCA-salt rat was reduced by SAHA treatment (Table 1) .
Organ bath studies
Thoracic aortic rings from DOCA-salt rats showed unaltered maximal responses to noradrenaline and sodium nitroprusside across all treatment groups ( Figure 5A & 5B) with minimal relaxation responses to acetylcholine suggesting pronounced endothelial dysfunction ( Figure 5C ). Treatment with SAHA normalized this decreased response to acetylcholine.
DISCUSSION
Cardiovascular remodelling following chronic pathophysiological stress includes hypertension, hypertrophy and fibrosis, ultimately leading to an enlarged and more rigid myocardium, together with electrical conduction changes and endothelial dysfunction (Weber, 1996; Weber et al, 1993) . While histone deacetylase inhibitors (HDACi) have been reported to be anti-inflammatory (Halili et al, 2009 ) and to attenuate cardiac hypertrophy (Antos et al, 2003; Gallo et al, 2008; Kee et al, 2006; Kong et al, 2006) , we have now shown that the broad spectrum (class I and II) HDACi, SAHA (25 mg kg -1 day -1 ), can also attenuate perivascular and interstitial cardiac fibrosis, as well as hypertension, electrical changes and endothelial dysfunction associated with DOCA-salt induced hypertension in rats. Functionally, this decreased fibrosis was associated with markedly reduced cardiac stiffness.
Inflammation is the key initiator of cardiac extracellular matrix remodelling by allowing the infiltration of inflammatory cells and activating fibroblasts (Nicoletti & Michel, 1999; Rutschow et al, 2006) . A single oral dose (0.1-25 mg kg -1 ) of SAHA reduced cytokines (TNF, IL1, IL6, IFN) in the circulation of mice treated with LPS (Leoni et al, 2002) . This is in accordance with our findings of diverse cytokine suppression monitored in DOCA-salt rats after chronic SAHA treatment, and is consistent with a broad-spectrum anti-inflammatory response to SAHA in rats.
Responses to injury in the heart share many features in common with wound healing, inflammation and fibrosis observed in other tissues, including lung, liver, kidney and skin (Brown et al, 2005b; Friedman, 1999; Kupper & Groves, 1995; Sime et al, 1998; Weber, 1997; Zalewski & Shi, 1997) . The common sequence of events that occurs in response to an inflammatory insult can be summarized as haemostasis; recruitment of circulating immune-inflammatory cells; macrophage activation; activation of fibroblasts and formation of a provisional matrix; and remodelling of the granulomatous scar (Brown et al, 2005b; Davidson, 1992; Weber, 1996) . These responses from activated immune-inflammatory cells are regulated by specific circulating cytokines and growth factors (Brown et al, 2005b) . In relation to inflammation and cardiac fibrosis, our previous study showed that a phospholipase A2 inhibitor, KH-064, also markedly attenuated fibrosis in the hypertensive heart without decreasing the infiltration of inflammatory cells . Other common anti-inflammatory drugs such as aspirin also decrease collagen deposition and prevent oxidative stress-induced cardiovascular remodelling in infarcted rats and angiotensin II-induced hypertensive rats, respectively (Van Kerckhoven et al, 2000; Wu et al, 2004) .
The importance of histone acetylation in the aetiology of cardiac remodelling has been highlighted by the regulation of the hypertrophic response of the heart by selective HDACi (Gusterson et al, 2003; Kong et al, 2006; Lu et al, 2000; Zhang et al, 2002) . HDACs modulate the divergent stress-response pathways activated during cardiac remodelling (Kong et al, 2006; McKinsey & Olson, 2004 ). The precise HDAC isoforms responsible for cardiovascular remodelling in vivo are still controversial, with evidence that class I (HDACs 1, 2, 3, 8 and 11), II (HDACs 4, 5, 6, 7, 9 and 10) and III (sirtuins) HDACs have pro-hypertrophic, anti-hypertrophic and anti-apoptotic functions in cardiomyocytes, respectively (McKinsey & Kass, 2007; McKinsey & Olson, 2004; Verdin et al, 2003; Zhang et al, 2002) .
HDACs and pro-inflammatory cytokines have been implicated in a wide variety of inflammatory diseases (Halili et al, 2009) , including rheumatoid arthritis (Choo et al, 2008) , systemic lupus erythematosus (SLE) (Blanchard & Chipoy, 2005) , asthma (Bhavsar et al, 2008) , inflammatory lung diseases (Adcock et al, 2005; Bhavsar et al, 2008) , atherosclerosis, hemorrhagic shock, diabetes, inflammatory bowel diseases, osteoporosis, macular degeneration, neurodegenerative and CNS diseases (Halili et al, 2009) , with therapeutic effects of HDACi in many animal models of inflammatory diseases (Blanchard & Chipoy, 2005) . SAHA suppressed cytokine production and nitric oxide release both in vivo and in vitro, possibly by regulating the expression of genes that control the synthesis of cytokines and nitric oxide or hyperacetylating other targets (Leoni et al, 2002) . There have been relatively few studies where rats have been chronically dosed with SAHA. Wise et al (2008) administered SAHA at oral doses of 0 to 150 mg kg -1 as a suspension in water with 1.0% (w/v) carboxymethylcellulose sodium and 0.5% (v/v) polysorbate 80 for up to 14 weeks to test changes in male and female fertility in rats. In the in vivo model of concanavalin A-induced hepatic injury, a model that is TNF and IL-18 dependent (Faggioni et al, 2000) , a single dose of SAHA (50 mg kg -1 ) reduced the injury by 50% (Leoni et al, 2002) . Oral treatment in mice with SAHA (50 mg kg -1 ) for 8 days reduced the clinical and cytokine abnormalities in dextran sulphate sodium-induced colitis (Glauben et al, 2006) . SAHA was also effective at doses of less than 50 mg kg -1 as an antiinflammatory compound in rodent models of rheumatic arthritis, endotoxemia, hepatic injury and colitis (Leoni et al, 2002; Lin et al, 2007) . In combination, this in vivo and in vitro information strongly suggests that the dose of SAHA used in this study, 25mg kg -1 day -1 , is in the range used in previous studies and is an effective dose to show anti-inflammatory effects (Halili et al, 2009) .
Inappropriate fibroblast hyperplasia is a hallmark of fibrosis. Myofibroblasts, which are specially differentiated fibroblasts exhibiting contractile properties and expressing smooth muscle -actin, play an important role in contracture of the granulomatous wound (Brown et al, 2005b) . Myofibroblasts have been identified in myocardial scars as the predominant source of collagen (Willems et al, 1994) . Macrophages are also localized with myofibroblasts in the NO-deficient model of fibrosis (Koyanagi et al, 2000) and isoprenaline-induced model of myocardial injury (Nakatsuji et al, 1997) . In addition, macrophage infiltration preceded the presence of myofibroblasts and clusters of macrophages were located in close proximity to myofibroblasts (Vyalov et al, 1993) , suggesting a role for inflammation in fibroblast activation and differentiation. Further, MMPs are important enzymes in regulating cardiovascular remodelling. Some hydroxamate derivatives inhibit the expression or activity of MMPs (Leung et al, 2000; Halili et al 2009) , but for SAHA we did not observe regulatory effects on the secretion of MMP-1, -2, -3, -8, -9, -10 or -13 or TIMP-1, -2 or -4 into the culture medium of human monocyte-derived macrophages as measured by antibody array. In gelatin zymography experiments, SAHA (5 or 50 M) had no effect on purified MMP-2 or -9 activities whereas the high concentration of 500 M showed a modest inhibition of MMP-2 activity (data not shown). Further, responses to MMP inhibitors differ from those shown with SAHA in this study: the tetracycline, doxycycline, did not change collagen area fraction during post-infarction left ventricular remodelling (Villarreal et al, 2003) . This suggests that an anti-inflammatory mechanism for SAHA, reducing circulating cytokines, and thereby reducing infiltrating inflammatory cells and arachidonic acid metabolites, rather than MMP inhibition, may be responsible for the reduced collagen deposition in the perivascular and interstitial areas in the DOCA-salt hypertensive heart.
Our results also show that treatment with SAHA attenuated the increased wet weights of DOCA-salt hypertensive hearts. Since inflammation initiates fibrosis without affecting hypertrophy (Kagitani et al, 2004; Kuwahara et al, 2004) , the antiinflammatory effects of SAHA may have little to do with this attenuation of ventricular hypertrophy. Class I HDACs (HDAC 1, 2 and 3) exhibited prohypertrophic properties (McKinsey & Kass, 2007; McKinsey & Olson, 2004; Trivedi et al, 2007; Verdin et al, 2003) and also increased cardiac myocyte proliferation during cardiac development in transgenic mice studies (Trivedi et al, 2008) . Further, the HDACi, valproic acid, reduced ventricular hypertrophy and remodelling in infarcted rats probably by repressing pro-hypertrophic genes (Lee et al, 2007) . This suggests that compounds that inhibit at least class I HDACs attenuate ventricular hypertrophy probably by repressing pro-hypertrophy genes or inducing cell cycle arrest.
Cardiac remodelling induced by DOCA-salt treatment is characterized by a decrease in the expression, current density and function of cardiac potassium channels (Ito and Ik), prolonging the action potential (Momtaz et al, 1996; Capuano et al, 2002) . The DOCA-salt rat suffers from cardiac electrical disturbances characterized by an increase in spontaneous arrhythmias (Momtaz et al, 1996; Capuano et al, 2002) . This prolongation of the action potential can be markedly attenuated by treatment with the NO-precursor, L-arginine or a selective antagonist of ET A receptors (Allan et al, 2005) concurrent with decreased cardiac fibrosis. Further, circulation pro-inflammatory compounds such as TNF can prolong the action potential by suppressing the delayed rectifier K + current (Wang et al, 2004) . Thus, the improved electrical conductance of the DOCA-salt hearts with SAHA treatment can be attributed to its anti-fibrotic effects.
The increase in systolic blood pressure in the DOCA-salt rats was attenuated with SAHA treatment. Recent studies point to class III HDAC enzymes (sirtuins) as key regulators of vascular endothelial homeostasis controlling angiogenesis, vascular tone and endothelial dysfunction (Potente & Dimmeler, 2008) . Although SAHA has been identified as a broad spectrum class I and class II HDACi, it was shown to differentially regulate the sirtuins. In cultured neural cells, SAHA and other class I and II HDACi upregulated SIRT2, SIRT4 and SIRT7 and downregulated SIRT1, SIRT5 and SIRT6 gene expression (Kyrylenko et al, 2003) . This supports the possibility that improved endothelial function and blood pressure in our study may be due to SAHA modulating the expression of sirtuins, which are vital in vascular endothelial homeostasis.
In summary, our results have shown that at least one HDACi has the potential to suppress cardiac fibrosis during development of hypertension in the rat heart. Although we attribute the observed pharmacological effects to broad-spectrum antiinflammatory activity, the possibility that the inhibition of global lysine acetylation, which alters various protein complexes and regulators of many major cellular functions including myocardial and vascular cell functions (Choudhary et al, 2009) , in being partly responsible cannot be ruled out. The results suggest that modulation of cardiac histone or non-histone protein acetylation by small molecule HDACi may be a viable approach to targeting intracellular signalling pathways that lead to cardiac remodelling and fibrosis. Since the HDACi studied is already available in humans for the treatment of lymphomas, the compound could be further examined in a clinical setting for preventing cardiac remodelling, particularly cardiac fibrosis. Litwin et al (1994) . IL17; 4, IP10; 5, IL2; 6, TNFa; 7, IL4; 8, MIP1a; 9, IFNg; 10, IL13; 11, IL1b; 12, CINC3; 13, IL1ra; 14, CNTF; 15, IL3; 16, GMCSF; 17, IL6; 18, CINC1; 19, RANTES; 20, thymus chemokine; 21, TIMP1; 22, LIX; 23, fractalkine; 24, Lselectin; 25, VEGF; 26, MIG; 27, sICAM; 28, IL10; 29, MIP3; 30 (control) . 
Legends
